New liquid drug tested for rare lung bleeding condition in ventilated patients
NCT ID NCT07556484
First seen May 05, 2026 · Last updated May 05, 2026
Summary
This early-stage study looks at how the body processes a liquid version of the drug avacopan in up to 6 patients with a rare autoimmune disease (ANCA vasculitis) who have severe lung bleeding and need a breathing machine. Researchers will measure drug levels in the blood over 72 hours and check markers of immune cell activity. The goal is to understand if this way of giving the drug works well in critically ill patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE ALVEOLAR HEMORRHAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.